Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneus Ltd. ( (AU:CMB) ) has provided an announcement.
Cambium Bio Limited has called an online general meeting for 16 March 2026, asking shareholders to approve the issue of 4,363,637 placement shares to Zheng Yang Biomedical Technology Co., Ltd. The proposed placement would lift the combined relevant interest and voting power of major shareholder Sebastian Tseng and ZYBT from 30.1% to as much as 41.3%, consolidating control in their hands.
An independent expert, Hall Chadwick, has concluded that the control transaction is fair and reasonable to non-associated shareholders, a key hurdle for the deal under Australian corporate law. Voting exclusions will apply to Tseng, ZYBT and their associates, with instructions set out for proxies and fiduciary holders, underscoring governance requirements as the company seeks shareholder approval for the capital raising and change in control dynamics.
The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.57 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.
More about Regeneus Ltd.
Cambium Bio Limited is an Australian biotechnology company focused on developing biomedical technologies. The company operates in the life sciences sector and targets investors interested in emerging medical and biotech opportunities.
Average Trading Volume: 8,536
Technical Sentiment Signal: Hold
Current Market Cap: A$13.55M
For an in-depth examination of CMB stock, go to TipRanks’ Overview page.